Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$4.26 USD
+0.16 (3.90%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $4.24 -0.02 (-0.47%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AQST 4.26 +0.16(3.90%)
Will AQST be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for AQST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AQST
Aquestive Therapeutics (AQST) Flat As Market Sinks: What You Should Know
Aquestive (AQST) Up as Anaphylm Pivotal Study Meets Goals
AQST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength?
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
Wall Street Bulls Look Optimistic About Aquestive Therapeutics (AQST): Should You Buy?
Other News for AQST
Aquestive Therapeutics initiated with bullish view at Raymond James
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
Crude Oil Surges 2%; Signet Jewelers Shares Spike Higher
XTIA, PSNL and LIDR among mid-day movers
What You Missed On Wall Street This Morning